OPTIMER PHARMACEUTICALS INC (OPTR)

Overview Price 13.29 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank 3 - HOLD Open Price $0.00 Previous Close $13.29 Daily Range $0.00 - $0.00 52-Week Range $6.81 - $17.95 Volume 0 OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies. Other Resources for OPTR Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Cubicin Drives Cubist Pharma January 20, 2012 Zacks Blog: Earnings Preview: Cubist Pharma January 17, 2012 Zacks Blog: Optimer Buoyant on Difficid Sales January 12, 2012 Zacks Blog: Cubist's Preliminary Sales Impress January 11, 2012 Zacks Blog: Pipeline Progress at Cubist Pharma December 15, 2011 OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies.   Brokerage Analyst Recommendations 10 Brokerage Firms Covering OPTR   Strong Buy 9 Buy 1 Hold 0 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.1   OPTR Ratings: BUY  SELL  HOLD OPTR Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 3 Buy 0 Sell   Top Buy Analysis BUY: OPTR Company: OPTIMER PHARMACEUTICALS INC. Points: -77.34 Start Price: $12.05 Start Date: 03/10/2009 11:22 AM JDShots P&P Score: 0.22 Recs: Recommended by Zacks Comments: 0 | Comment More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
rjm77me	99.92	08/10/11	Insiders are buying = will MARKET hold ground???	5	08/31/11
zantriocom	0.00	11/02/09	Zantrio.com Free Daily Stock Picks 11-2-09	0
Zacks_Analysts	0.00	01/20/12	Cubicin Drives Cubist Pharma - Analyst Blog	0
Zacks_Analysts	0.00	01/17/12	Earnings Preview: Cubist Pharma - Analyst Blog	0
Zacks_Analysts	0.00	01/12/12	Optimer Buoyant on Difficid Sales - Analyst Blog	0
Zacks_Analysts	0.00	01/11/12	Cubist's Preliminary Sales Impress - Analyst Blog	0
Zacks_Analysts	0.00	12/15/11	Pipeline Progress at Cubist Pharma - Analyst Blog	0
Zacks_Analysts	0.00	12/14/11	Optimer's Dificlir Cleared in EU - Analyst Blog	0
Zacks_Analysts	0.00	12/13/11	Cubist Pharma Buys Adolor - Analyst Blog	0
Zacks_Analysts	0.00	12/01/11	Optimer Moved Down to Neutral - Analyst Blog	0

Pages: [ 1 ]  2   3   4   5  >>

Commentary

BUY: OPTIMER PHARMACEUTICALS INC. (OPTR) Start Price: $12.05 Points: -77.34 Created: 03/10/2009 Recommended by Zacks Comments: 0 | Comment JDShots Recs:

BUY: OPTIMER PHARMACEUTICALS INC. (OPTR) Start Price: $10.96 Points: +15.55 Created: 11/08/2011 buy Comments: 0 | Comment hensonguess Recs:

BUY: OPTIMER PHARMACEUTICALS INC. (OPTR) Start Price: $7.30 Points: +87.65 Created: 05/17/2008 Comments: 1 | Comment Peterjr Recs:

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
hensonguess	97.69	BUY	Week or Less	11/08/2011	$10.96	$13.31 (+0.79%)	+21.49%	+5.94%	+15.55	view close
JDShots	0.22	BUY	Week or Less	03/10/2009	$12.05	$13.31 (+0.79%)	+10.50%	+87.84%	-77.34	view close
Peterjr	99.14	BUY	Six Months to a Year	05/17/2008	$7.30	$13.31 (+0.79%)	+82.40%	-5.25%	+87.65